

**PRESENTATION SCHEDULE****WEDNESDAY, MAY 12, 2021****Track 1A (12:00 to 1:20)****Critical Care**

<b>12:00 to 12:20</b>	"Evaluation Of Viscoelastic Test-Guided Blood And Factor Transfusions In Cirrhotic Patients" <b>Nina Srour (PGY1), Houston Methodist Hospital - Houston, TX</b>
<b>12:20 to 12:40</b>	"Description and Impact of Anti-Xa Levels in Patients Presenting with Acute Ischmic Stroke Taking Apixaban or Rivaroxaban" <b>Olivia Kreidler (PGY1), Houston Methodist Hospital - Houston, TX</b>
<b>12:40 to 1:00</b>	"Thromboelastography Platelet Mapping in Patients with Traumatic Intracranial Hemorrhage on Anti-platelet Medication" <b>Cody Wise (PGY1), Sanford Medical Center Fargo - Fargo, ND</b>
<b>1:00 to 1:20</b>	"Comparison of Norepinephrine to Phenylephrine on the Proportion of Time with Rate Control in Septic Shock Patients with Atrial Fibrillation and Rapid Ventricular Response" <b>Gianna Vitale (PGY2), Sanford Medical Center Fargo - Fargo, ND</b>

**Program Objectives:**

1. Describe the types and amounts of blood/factor products administered based on a TEG-guided transfusion strategy.
2. Describe the utility of apixaban and rivaroxaban anti-Xa levels in patients presenting with acute ischemic stroke.
3. Assess the utility of TEG-PM in patients with traumatic intracranial hemorrhage on anti-platelet medication.
4. Assess the difference of proportion of time in rate control in septic shock patients with atrial fibrillation and rapid ventricular response who received norepinephrine versus those transitioned phenylephrine.

**Track 1B (12:00 to 1:20)****Infectious Disease**

<b>12:00 to 12:20</b>	"Effects of Implementation of the BioFire® Pneumonia Panel on Antibiotic De-escalation" <b>Molly Miller (PGY2), Nebraska Medicine - Omaha, NE</b>
<b>12:20 to 12:40</b>	"An Analysis of Vancomycin Pharmacokinetics in Intravenous Drug Users" <b>Gadison Quick (PGY1), Truman Medical Center - Kansas City, MO</b>
<b>12:40 to 1:00</b>	"Investigation of Empiric Oral Antibiotics in the Treatment of Extended Spectrum Beta Lactamase Urinary Tract Infections" <b>Matthew Bjornstad (PGY1), Regions Hospital - St. Paul, MN</b>
<b>1:00 to 1:20</b>	"Effect of MRSA Nasal PCR Results on Vancomycin Therapy in Hospital-acquired and Ventilator-Associated Pneumonia" <b>Megan Waibel (PGY1), Regions Hospital - Saint Paul, MN</b>

**Program Objectives:**

1. Describe the impact of implementation of a PCR Pneumonia Panel on time to de-escalation of antibiotics in ICU patients being treated for pneumonia.
2. Describe the correlation between the use of illicit intravenous drugs and alterations to vancomycin pharmacokinetics.
3. Identify what oral antibiotics may have better susceptibility patterns against ESBL Enterobacteriaceae in urinary tract infections.
4. Describe the clinical utility of an MRSA nasal PCR in an ICU population.

**Track 1C (12:00 to 1:20)****Internal Medicine**

<b>12:00 to 12:20</b>	"Staff Perceptions of and Interventions Completed by an Emergency Department Pharmacist in a Rural Health System" <b>Jackson Nelson (PGY1), Lake Region Healthcare - Fergus Falls, MN</b>
<b>12:20 to 1:20</b>	"Evaluation of Anti-Xa Levels in Patients with Venous Thromboembolism within the First 48 Hours of Anticoagulation with Unfractionated Heparin" <b>Abe Karimi (PGY2), Lily Koob (PGY1), and Xiaoxiao Qi (PGY1), Avera McKennan Hospital &amp; University Health Center - Sioux Falls, SD</b>

**Program Objectives:**

1. Identify interventions made by pharmacist in the emergency department.
2. Discuss the efficacy of the study institution's unfractionated heparin (UFH) dosing protocol in patients with venous thromboembolism within the first 48 hours of treatment initiation.

**Track 1D (12:00 to 1:20)****Pharmacy Practice**

<b>12:00 to 12:20</b>	"Pharmacist Opinions Regarding Conference Attendance and Financial Obligations" <b>Lauren Pratt (PGY1), Hennepin Healthcare - Minneapolis, MN</b>
<b>12:20 to 12:40</b>	"Process Improvement: Increasing Naloxone Access After Opioid Overdose" <b>Alyssa Boyle (PGY1), Hennepin Healthcare - Minneapolis, MN</b>
<b>12:40 to 1:00</b>	"Multi-Step Order Transmittal (MSOT) Impact on Specialty Prescription Capture Rate" <b>Alice Callahan (PGY1), Hennepin Healthcare - Minneapolis, MN</b>
<b>1:00 to 1:20</b>	"Implementation of Centralized Pharmacy Order Verification in a Large Multi-hospital Health-system" <b>Niha Zafar (PGY1), Houston Methodist Hospital - Houston, TX</b>

**Program Objectives:**

1. Describe the attitudes of pharmacists towards the importance of conference attendance and who should hold the financial responsibility of the costs to attend.
2. Describe practice enhancement and system optimization techniques that have the ability to improve naloxone prescribing and dispensing rates after non-fatal opioid overdose.
3. Describe the MSOT process. Understand MSOT applicability to prescription capture. Assess available data pre- and post-MSOT.
4. Discuss the processes to successfully implement centralized pharmacy order verification services in a large multi-hospital health-system.

**Track 1E (12:00 to 1:20)**

**Primary/Ambulatory Care**

<b>12:00 to 12:20</b>	"Evaluating Appropriate Dosing of Direct Oral Anticoagulants in a Health System" <b>Nirali Patel (PGY1), University of Missouri Health System - Columbia, MO</b>
<b>12:20 to 12:40</b>	"Impact of Population Management on Pharmacist Interventions for Patients with Heart Failure at VA Nebraska-Western Iowa Healthcare System" <b>Michelle Paulsen (PGY1), VA Nebraska-Western Iowa Health Care System - Grand Island Division - Grand Island, NE</b>
<b>12:40 to 1:00</b>	"Evaluation of Patients Prescribed Gabapentin with Renal Impairment at VA Nebraska-Western Iowa Health Care System" <b>Kristen Grimaldi (PGY1), VA Nebraska-Western Iowa Health Care System - Grand Island Division - Grand Island, NE</b>
<b>1:00 to 1:20</b>	"Development of a Population Health Management Report to Expand Clinical Pharmacist Management of Gout in a Veterans Affairs Medical Center" <b>Jessica Berei (PGY2), VA Nebraska-Western Iowa Health Care System - Grand Island Division - Grand Island, NE</b>

**Program Objectives:**

1. To evaluate if patients are being prescribed appropriate doses of DOACs in a large health system, as well as the evaluation of safety and efficacy with inappropriate dosing.
2. Relate resident-led education regarding a new population management strategy to clinical encounters and interventions for heart failure completed by ambulatory care pharmacists.
3. Review appropriateness of total daily doses of gabapentin in patients with renal impairment.
4. Discuss the effectiveness of utilizing a population health management report to expand pharmacist management of gout.

**Track 1F (12:00 to 1:20)**

**Hematology/Oncology**

<b>12:00 to 12:20</b>	"Evaluation and Impact of a Transitions of Care Pharmacist for Malignant Hematology" <b>Megan Czmowski (PGY2), Sanford Roger Maris Cancer Center - Fargo, ND</b>
<b>12:20 to 12:40</b>	"Retrospective review of adverse reaction events secondary to checkpoint inhibitor immunotherapies and their management at a community cancer clinic" <b>Anh Tang (PGY1), Freeman Health System - Joplin, MO</b>
<b>12:40 to 1:00</b>	"Impact on Patient-Centered Outcomes for Oral Chemotherapy Prescriptions Filled at Monument Health Home+ Specialty Pharmacy Versus Other Channels" <b>Abigale Ferdinand (PGY2), Monument Health Rapid City Hospital - Rapid City, SD</b>
<b>1:00 to 1:20</b>	"Evaluation of Leucovorin Rescue Dosing Strategies in Patients Receiving High-Dose Methotrexate" <b>Rachel Mehringer (PGY1), SSM Health Saint Louis University Hospital - Saint Louis, MO</b>

**Program Objectives:**

1. Discuss the impact of a transitions of care pharmacist for malignant hematology patients.
2. Assess the response treatment of adverse reaction events secondary to CILs at a community cancer center, compared to current National Comprehensive Cancer Network (NCCN) guidelines.
3. Examine patient-centered outcomes for those who fill their oral chemotherapy at Monument Health Home+ Specialty Pharmacy vs those who fill via a different channel.
4. Identify if flat-dose leucovorin rescue dosing strategies are non-inferior to a nomogram approach in preventing toxicity following high-dose methotrexate administration.

**Track 1G (12:00 to 1:20)**

**Transplant**

<b>12:00 to 12:20</b>	"Immunosuppression Modifications after CMV or BKV Viremia in Kidney Transplant Recipients" <b>Casey Dubrawka (PGY2), Barnes-Jewish Hospital - Saint Louis, MO</b>
<b>12:20 to 12:40</b>	"Tacrolimus XR Dosing in Kidney Transplant Patients" <b>Michele McCloskey (PGY2), Barnes-Jewish Hospital - St. Louis, MO</b>
<b>12:40 to 1:00</b>	"Belatacept Conversion in Kidney Transplant Recipients" <b>Roberto Montealegre (PGY1), Barnes-Jewish Hospital - St. Louis, MO</b>
<b>1:00 to 1:20</b>	"Transplantation of Hepatitis C Viremic Donor Organs to Hepatitis C Nonviremic Recipients: A Retrospective Review" <b>Madeline Blaha (PGY1), Nebraska Medicine - Omaha, NE</b>

**Program Objectives:**

1. Describe impact of antimetabolite discontinuation after CMV or BKV viremia and identify risk factors for rejection in kidney transplant recipients.
2. To determine initial weight-based dose to avoid supratherapeutic or subtherapeutic levels in our patient population.
3. Efficacy of belatacept vs standard of care in kidney transplants with slow or delayed graft function.
4. Describe outcomes associated with Hepatitis C viremic organ donation among liver, kidney, heart, and lung transplant recipients.

**Track 2A (1:30 to 3:30)**

**Critical Care**

<b>1:30 to 1:50</b>	"Validation of the Medication Regimen Complexity Intensive Care Unit (MRC-ICU) Scoring Algorithm with an Expanded Intervention Capture of Medication Therapy Management (MTM) Services" <b>Brady Diveley (PGY2), CoxHealth - Springfield, MO</b>
<b>1:50 to 2:10</b>	"Assessment of Clonidine for Dexmedetomidine Discontinuation" <b>Megan Morgan (PGY1), CoxHealth - Springfield, MO</b>
<b>2:10 to 2:30</b>	"Evaluate the impact of adjuvant midodrine on the use of intravenous vasopressors in adult patients with septic shock in the intensive care unit" <b>Lauren Renschler (PGY1), CoxHealth - Springfield, MO</b>
<b>2:30 to 2:50</b>	"Management of alcohol withdrawal syndrome: symptom-triggered vs. fixed-schedule benzodiazepine dosing and intensive care unit admission rates" <b>Megan Smith (PGY1), AdventHealth Shawnee Mission - Shawnee Mission, KS</b>
<b>2:50 to 3:10</b>	"Implementation of a clonidine-based protocol for dexmedetomidine-related withdrawal symptoms in a community hospital intensive care unit" <b>Leila Brizzee (PGY1), AdventHealth Shawnee Mission - Merriam, KS</b>
<b>3:10 to 3:30</b>	"Integrating and Assessing the role of an Emergency Medicine Pharmacist on key outcomes in Ischemic Stroke" <b>Eesha Patel (PGY1), MercyOne Waterloo Medical Center - Waterloo, IA</b>

**Program Objectives:**

1. Describe the relationship between the MRC-ICU criticality score and the number of pharmacist interventions.
2. To outline safety and efficacy parameters of a clonidine taper for dexmedetomidine discontinuation.
3. To assess the impact of adjuvant midodrine on the use of intravenous vasopressors in adult patients with septic shock in the intensive care unit.
4. Determine the most appropriate benzodiazepine dosing regimen for treatment of alcohol withdrawal syndrome (AWS) on the medical floors of a hospital.
5. Review/compare incidence of dexmedetomidine-related rebound hypertension in patients receiving prolonged dexmedetomidine infusions before & after implementation of a clonidine transition protocol.
6. To assess the impact of an Emergency Room (ER) pharmacist in critical disease states, such as Acute Ischemic Stroke, which are considered time sensitive.

**Track 2B (1:30 to 3:30)**

**Infectious Disease**

<b>1:30 to 1:50</b>	"Nasal Methicillin-Resistant Staphylococcus aureus (MRSA) PCR screening for de-escalation of empiric MRSA antimicrobial coverage: a single-center, retrospective analysis" <b>Shanee Hanning (PGY1), Monument Health Rapid City Hospital - Rapid City, SD</b>
<b>1:50 to 2:10</b>	"Assessment of Compliance with Order Set and Bundle for Management of Staphylococcus Aureus Bacteremia" <b>Ryan Flynn (PGY1), Monument Health Rapid City Hospital - Rapid City, SD</b>
<b>2:10 to 2:30</b>	"Improving Vancomycin Dosing Management in Hemodialysis Patients" <b>An Le (PGY1), United Hospital - Saint Paul, MN</b>
<b>2:30 to 2:50</b>	"Impact of Two-Step Testing for Clostridium difficile Infections on Antimicrobial Use at United Hospital" <b>Tony Kanayinkal (PGY1), United Hospital - Saint Paul, MN</b>
<b>2:50 to 3:10</b>	"Vancomycin AUC:MIC Calculations: Comparing Bayesian Software to an In-House Calculator" <b>Allison Hotop (PGY1), SSM Health St. Mary's Hospital - Richmond Heights, MO</b>
<b>3:10 to 3:30</b>	"Clinical utility of methicillin-resistant Staphylococcus aureus (MRSA) nasal PCR assays beyond respiratory infections" <b>Haley Noeldner (PGY1), Iowa Methodist Medical Center - Des Moines, IA</b>

**Program Objectives:**

1. Describe the data supporting the use of nasal MRSA PCRs in the de-escalation of empiric antibiotic regimens.
2. Describe the importance in obtaining a TTE or TEE in patients with S. aureus bacteremia, and the impact it has on the patient's treatment course.
3. Evaluate and optimize our current vancomycin dosing protocol to promote the effectiveness and safety of vancomycin intravenous therapy in hemodialysis patients.
4. Identify medication usage, cost-effectiveness, and patient safety from a recently implemented Clostridium difficile Two-Step Testing method.
5. Describe which method of predicting AUC more accurately reflects a patient's actual AUC.
6. Discuss the potential role(s) MRSA nasal PCR assays could play in antimicrobial stewardship beyond the current, well-documented role in respiratory infections.

**Track 2C (1:30 to 2:30)**

**Internal Medicine**

<b>1:30 to 1:50</b>	"Assessment of a Pharmacy Resident Transitions of Care Pilot Program" <b>Larissa Gabler (PGY1), Hennepin Healthcare - Minneapolis, MN</b>
<b>1:50 to 2:10</b>	"Factors influencing hospital length of stay in patients with cellulitis" <b>Emma Gargala (PGY2), Hennepin Healthcare - Minneapolis, MN</b>
<b>2:10 to 2:30</b>	"Effect of Intravenous Azithromycin on the QT Interval of ICU Patients" <b>Saidee Oberlander (PGY1), Iowa Methodist Medical Center - Des Moines, IA</b>

**Program Objectives:**

1. Be able to discuss the impact that a pharmacy resident-led transitions of care program can have on a healthcare system and on patient care.
2. To identify and evaluate what factors influence length of stay in patients admitted with non-purulent skin and soft tissue infections.
3. Discuss the effect of antibiotic therapy on QTc interval in critically ill patients with community acquired pneumonia.

**Track 2D (1:30 to 2:50)**

**Pharmacy Practice**

<b>1:30 to 1:50</b>	"Improving Warfarin Discharge Process at a Community-Based Hospital" <b>Thu Ha Nguyen (PGY1), United Hospital - St. Paul, MN</b>
<b>1:50 to 2:10</b>	"Impact of implementing a transitions of care discharge counseling program for new cardiac medications on patient satisfaction survey scores at Freeman Health System" <b>Evan Roberts (PGY1), Freeman Health System - JOPLIN, MO</b>
<b>2:10 to 2:30</b>	"Assessment of Potential Cost Avoidance with Dalbavancin in Emergency Department Use" <b>Andrew Vogler (PGY1), Mercy Hospital Springfield - Springfield, MO</b>
<b>2:30 to 2:50</b>	"Outpatient Insulin Regimens and the Effect on Inpatient Hypoglycemia" <b>Hannah Page (PGY1), Mercy Hospital Joplin - Joplin, MO</b>

**Program Objectives:**

1. Assess completeness of warfarin discharging recommendations by pharmacists & determine barriers for pharmacists to provide a written complete warfarin discharge recommendation in warfarin progress note.
2. The purpose of this study is to provide patients prescribed new cardiac medications with discharge medication education from our cardiac floor and evaluate the new service via patient satisfaction survey results.
3. Discuss the impact dalbavancin use in the emergency department has on admissions, length of stay, and cost avoidance.
4. Identify the relationship between insulin regimens started upon admission and hypoglycemic events within 48 hours of admission.

**Track 2E (1:30 to 2:50)**

**Primary/Ambulatory Care**

<b>1:30 to 1:50</b>	"Metoprolol and CYP2D6: A Retrospective Analysis Evaluating Genotype-based Outcomes" <b>Savannah Suchor (PGY1), Sanford USD Medical Center - Sioux Falls, SD</b>
<b>1:50 to 2:10</b>	"Direct Oral Anticoagulant (DOAC) management for outpatients as an additional clinical service for our established anticoagulation clinics" <b>Ashraf Amadou (PGY1), Unitypoint-Allen Hospital - Waterloo, IA</b>
<b>2:10 to 2:30</b>	"Clinical Outcomes Associated with Insulin Titration Program in an Outpatient Clinic" <b>Bailey Archer (PGY1), SSM Health St. Mary's Hospital - St. Louis - St. Louis, MO</b>
<b>2:30 to 2:50</b>	"An Assessment of Pharmacist-Led Annual Wellness Visits: Patient and Provider Satisfaction and Recommendations Made" <b>Brooke Nibbelink (PGY1), South Dakota State University College of Pharmacy and Allied Health Professions and Lewis Drug - Sioux Falls, SD</b>

**Program Objectives:**

1. Describe the relationship between metoprolol and CYP2D6 loss of function polymorphisms in regards to adverse effects and dose.
2. Discuss this new service line.
3. Describe the impact a pharmacist-led insulin titration program in an outpatient clinic has on clinical outcomes.
4. Explain the potential benefits and acceptance of having Medicare Annual Wellness Visits conducted by clinical pharmacists in the ambulatory care setting.

**Track 2F (1:30 to 3:30)**

**Hematology/Oncology**

<b>1:30 to 1:50</b>	"Evaluating the recurrence of immune-mediated toxicities in cancer patients after rechallenge with a checkpoint inhibitor" <b>Shelby Van Driel (PGY1), Avera McKennan Hospital &amp; University Health Center - Sioux Falls, SD</b>
<b>1:50 to 2:10</b>	"Assessment of the impact of oral cryotherapy on incidence of mucositis with high-dose melphalan conditioning for autologous hematopoietic stem cell transplant" <b>Justine Wilson-Miller (PGY2), Avera McKennan Hospital and University Health Center - Sioux Falls, SD</b>
<b>2:10 to 2:30</b>	"An evaluation of an unfractionated heparin (UFH) dose-banded protocol on time to therapeutic activated prothrombin time (aPTT) in the obese versus non-obese population with acute, venous thromboembolism (VTE) at an academic medical center" <b>Austin Miller (PGY1), Truman Medical Center - Kansas City, MO</b>
<b>2:30 to 2:50</b>	"Immunotherapy Versus Chemoimmunotherapy in Advanced Non-small Cell Lung Cancer" <b>Blake Buzard (PGY2), Houston Methodist Hospital - Houston, TX</b>
<b>2:50 to 3:10</b>	"Evaluation of Folfx Chemotherapy Dosing in Obesecolorectal Cancer Patients" <b>Breanna Hinman (PGY1), Houston Methodist Hospital - Houston, TX</b>
<b>3:10 to 3:30</b>	"Rate of Cytomegalovirus (CMV) Viremia in Allogenic Hematopoietic Stem Cell Transplant (HSCT) Patients" <b>Ashka Patel (PGY2), Houston Methodist Hospital - Houston, TX</b>

**Program Objectives:**

1. Describe recurrence of immune-mediated toxicities after rechallenging with an immune checkpoint inhibitor in patients that had previously experienced immune-mediated toxicity requiring treatment with a corticosteroid.
2. Determine the benefits of cryotherapy with high-dose melphalan conditioning chemotherapy.
3. Describe the difference between obese and non-obese patients in regards to time to first therapeutic aPTT and UFH infusion rate to determine clinical relevance to patient care.
4. Describe the number of completed cycles with immunotherapy compared to chemoimmunotherapy, particularly according to PD-L1 expression.
5. Describe the safety and tolerability of fluorouracil, oxaliplatin, and leucovorin (FOLFOLX) chemotherapy regimen dosing in obese colorectal cancer patients.
6. Evaluate the CMV viremia rates pre- and post- initiation of letermovir prophylaxis.

**Track 2G (2:30 to 3:30)**

**Cardiology**

<b>2:30 to 2:50</b>	"Comparison of Efficacy and Safety of Direct Oral Anticoagulants and Warfarin for Left Ventricular Thrombi" <b>Amanda Bernarde (PGY1), University of Missouri Health Care - Columbia, MO</b>
<b>2:50 to 3:10</b>	"Ticagrelor with anticoagulation versus clopidogrel with anticoagulation: comparing long-term bleed risk (TACCL-Bleeds)" <b>Molly McCord (PGY1), Sanford Medical Center Fargo - Fargo, ND</b>
<b>3:10 to 3:30</b>	"Evaluation of Interprofessional Collaboration with Inclusion of Ambulatory Care Pharmacists in a Patient Centered Medical Home Model on Heart Failure Transitions of Care and 30-day Readmission Rates" <b>Kyle Mick (PGY1), LMH Health - Lawrence, KS</b>

**Program Objectives:**

1. Describe the rate of LV thrombus resolution in patients treated with warfarin or DOACs as it relates to national and international guidelines.
2. Discuss the long-term safety of ticagrelor in combination with anticoagulation.
3. Review the background of HF and readmission rates, Discuss outpatient pharmacist impact on readmission rates at a community health-system.

**Track 2H (1:30 to 2:30)**

**Community Practice**

<b>1:30 to 1:50</b>	"The Impact of Implementing a Community Pharmacist-Led Shingrix Vaccination Program in Collaboration with a Family Medicine Clinic" <b>Megan Flandro (PGY1), Creighton University - Omaha, NE</b>
<b>1:50 to 2:10</b>	"Characterizing Patients Who Use a Bubble Packaging Service in a Community Pharmacy and Examining Its Impact on Medication Adherence" <b>Miranda Staab (PGY1), Creighton University - Elkhorn, NE</b>
<b>2:10 to 2:30</b>	"Impact of Pharmacist-Led Employee Health Screenings on Cardiovascular Risk" <b>Ashley Kells (PGY1), The University of Kansas School of Pharmacy &amp; Dillons Pharmacy - Wichita, KS</b>

**Program Objectives:**

1. To assess the efficacy of a Shingrix vaccine program in collaboration with a family medicine clinic.
2. Assess effectiveness of bubble packaging on medication adherence and clinical outcomes such as A1c, blood pressure and lipid levels.
3. Describe the impact of annual employee health screenings on cardiovascular risk with pharmacist-led clinical interventions.

**Track 2I (1:30 to 2:30)**

**Transplant**

<b>1:30 to 1:50</b>	"Time to therapeutic tacrolimus levels and association with acute cellular rejection and de novo donor-specific antibody development in lung transplant recipients" <b>Corey Dinunno (PGY1), Houston Methodist Hospital - Houston, TX</b>
<b>1:50 to 2:10</b>	"Intravenous immunoglobulin in heart transplant recipients with hypogammaglobulinemia and infection" <b>Johnny Hoang (PGY2), Houston Methodist Hospital - Houston, TX</b>
<b>2:10 to 2:30</b>	"Impact of Positive Donor Cultures on Postoperative Lung Transplantation Infectious Outcomes" <b>Anna Curtis (PGY2), Houston Methodist Hospital - Houston, TX</b>

**Program Objectives:**

1. Evaluate the impact time to therapeutic tacrolimus levels immediately post-transplant has on development of immune outcomes amongst lung transplant recipients.
2. Assess use of intravenous immunoglobulin in heart transplant recipients with hypogammaglobulinemia on rates of infection.
3. Describe the impact of positive donor cultures on postoperative lung transplantation infectious outcomes.

**Track 2J (1:30 to 2:30)**

**Pediatrics/Neonatology**

<b>1:30 to 1:50</b>	"The Implementation and Assessment of a Pharmacist-Focused Pediatric Emergency Care Program in a Community Hospital" <b>Nicole Nehring (PGY1), SSM Health St. Clare - Fenton - Fenton, MO</b>
<b>1:50 to 2:10</b>	"Evaluation and implementation of KIDs list medication safety in a university health system" <b>Victoria Anderson (PGY1), University of Missouri Women's and Children's Hospital - Columbia, MO</b>
<b>2:10 to 2:30</b>	"Dornase Alfa for the Treatment of Bronchiolitis in Pediatric Patients: A Retrospective Cohort Study" <b>Kassy Vettleson (PGY1), Sanford USD Medical Center - Sioux Falls, SD</b>

**Program Objectives:**

1. To identify a difference in pharmacists' perception of preparedness or knowledge base after undergoing the pediatric emergency care program.
2. Discuss opportunities to improve pediatric medication safety using the KIDs list as a guide.
3. Describe the effects of dornase alfa compared to standard of care treatment for bronchiolitis in mechanically ventilated pediatric patients.

**Track 3A (3:40 to 5:00)**

**Critical Care**

<b>3:40 to 4:00</b>	"Evaluation of Post-TPA Events to Determine Appropriate ICU Monitoring Duration for Ischemic Stroke Patients" <b>James Reimer (PGY1), SSM Health Saint Louis University Hospital - Saint Louis, MO</b>
<b>4:00 to 4:20</b>	"Retrospective review of delirium incidence in fixed-dose ketamine infusions compared to titratable ketamine infusions in critically ill patients" <b>Taylor Schumacher (PGY1), SSM Health DePaul Hospital - Bridgeton, MO</b>
<b>4:20 to 4:40</b>	"Intermittent Benzodiazepines as Initial Sedation in Patients Requiring Mechanical Ventilation" <b>Cody Craven (PGY2), SSM Health Saint Louis University Hospital - Saint Louis, MO</b>
<b>4:40 to 5:00</b>	"The Impact of Pharmacokinetic Changes on the Achievement of Therapeutic Vancomycin Trough Levels for Patients in Septic Shock with Apparent Renal Dysfunction" <b>Smita Rausaria (PGY1), SSM Health St. Clare Hospital - Fenton, MO</b>

**Program Objectives:**

1. Identify patient factors associated with lower risk of developing complications that would necessitate ICU care beyond 12 hours post-TPA administration for acute ischemic stroke.
2. Describe the role of ketamine as a continuous infusion for analgosedation in critically ill patients.
3. Outline the rationale for using intermittently dosed benzodiazepines as an initial sedation strategy in mechanically ventilated patients.
4. Identify patients with septic shock with apparent renal dysfunction who are at risk of subtherapeutic vancomycin trough levels in the first 24 hours of therapy.

**Track 3B (3:40 to 5:00)**

**Infectious Disease**

<b>3:40 to 4:00</b>	"Implementation of a pharmacist-driven blood culture communication process in a non-profit community hospital" <b>Alexis Thumann (PGY1), Mercy Medical Center - Cedar Rapids - Cedar Rapids, IA</b>
<b>4:00 to 4:20</b>	"Extended-Infusion Versus Intermittent-Infusion Cefepime in the Treatment of Microbiologically-Confirmed Infections" <b>Marysa Wilson (PGY1), Bryan Medical Center - Gretna, NE</b>
<b>4:20 to 4:40</b>	"Evaluation of COVID-19 Admission Rates for Bamlanivimab and Casirivimab/Imdevimab" <b>Erica Rush (PGY1), Mosaic Life Care Medical Center - St. Joseph, MO</b>
<b>4:40 to 5:00</b>	"Two-level Kinetic Based Bayesian Population Model for Vancomycin Dose Management in Obese Patients" <b>Devinn Ashford (PGY1), Mosaic Life Care Medical Center - Saint Joseph, MO</b>

**Program Objectives:**

1. Define the process improvement implemented at Mercy Medical Center aimed at improving time to appropriate and optimal antimicrobial therapy.
2. To identify the impact of extended-infusion cefepime on the rate of clinical cure at 48 hours post-end-of-therapy or at time of discharge.
3. Review COVID-19 admission rates for patients treated with bamlanivimab or casirivimab/imdevimab.
4. Recognize guideline recommendations for vancomycin monitoring in obese patients and discuss application of Bayesian population models for AUC targeting.

**Track 3C (3:40 to 5:00)**

**Internal Medicine**

<b>3:40 to 4:00</b>	"Comparison of Parenteral Ketorolac Dosing for Acute Pain in Obstetric Patient Undergoing Cesarean Delivery in an Academic Medical Center" <b>Katie Luetkenhaus (PGY1), Truman Medical Centers - Kansas City, MO</b>
<b>4:00 to 4:20</b>	"Retrospective Analysis of Phenobarbital Use in Acute Alcohol Withdrawal Syndrome (AWS) for Hospitalized Patients" <b>Alex Weber (PGY1), MercyOne North Iowa Medical Center - Mason City, IA</b>
<b>4:20 to 4:40</b>	"Evaluation of Venous Thromboembolism Prophylaxis in Thrombocytopenic Patients with Active Cancer or Cirrhosis at a Community Hospital" <b>Lavinia Salama (PGY1), Southeast Hospital - Cape Girardeau, MO</b>
<b>4:40 to 5:00</b>	"Comparison of Anti-XA Versus APTT for patients transitioning from a Direct Oral Anticoagulant to an IV Heparin Infusion" <b>Scott Dingus (PGY1), Sanford USD Medical Center - Sioux Falls, SD</b>

**Program Objectives:**

1. Review the data supporting the use of 15 mg parenteral ketorolac in obstetric patients undergoing cesarean delivery.
2. Recall adverse effects associated with benzodiazepine overdose.
3. Identify risk factors of VTE events in patients with thrombocytopenia.
4. Discuss the safety and efficacy outcomes observed from a comparison of anti-Xa and aPTT monitoring for patients transitioning from a direct oral anticoagulant to a weight-based unfractionated heparin infusion.

**Track 3D (3:40 to 5:00)**

**Pharmacy Practice**

<b>3:40 to 4:00</b>	"Evaluation of Clinical Outcomes of Elexacaftor/Tezacaftor/Ivacaftor" <b>Olivia Howard (PGY1), University of Missouri Health Care - Columbia, MO</b>
<b>4:00 to 4:20</b>	"Improving the discharge medication process for patients after private hospitalization within a rural Veterans Affairs Healthcare System" <b>Abigail Cole (PGY1), VA Black Hills Health Care System - Fort Meade, SD</b>
<b>4:20 to 4:40</b>	"Determining Burnout of Pharmacists as Providers" <b>Nicole Henderson (PGY1), VA Eastern Kansas Health Care System - Topeka, KS</b>
<b>4:40 to 5:00</b>	"Review of Pharmacy Deprescribing Campaign within VISN23 VA Healthcare System" <b>Paige Nekola (PGY1), VA Nebraska-Western Iowa Health Care System - Lincoln - Lincoln, NE</b>

**Program Objectives:**

1. Describe the clinical outcomes and adverse reactions of Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) in patients at an academic medical center.
2. Describe the outcomes of a transitions of care program implemented in a rural VA hospital setting.
3. Characterize patterns of burnout in pharmacists in different clinical settings within the VA.
4. Explain the appropriate use of the "Deprescribe - See Progress Note" option in CPRS.

**Track 3E (3:40 to 4:40)**

**Primary/Ambulatory Care**

<b>3:40 to 4:00</b>	"Comparing the efficacy and safety of empagliflozin versus dulaglutide or liraglutide when added to insulin regimens in veterans with type 2 diabetes" <b>Matthew Wiemann (PGY1), Sioux Falls VA Health Care System - Sioux Falls, SD</b>
<b>4:00 to 4:20</b>	"Comparison Between Time to Goal Glycemic Control in Patient Self-Titration Versus Pharmacist-Driven Titration of Basal Insulin in a Veteran Population" <b>Krista Hayen (PGY1), Sioux Falls VA Health Care System - Sioux Falls, SD</b>
<b>4:20 to 4:40</b>	"Implementation of discharge follow-up phone calls and their effect on readmission rates in chronic obstructive pulmonary disease and heart failure patients" <b>Pascha Brim (PGY1), Cox Medical Center Branson - Branson, MO</b>

**Program Objectives:**

1. To identify whether there is a difference in efficacy and safety in veterans with type 2 diabetes who receive empagliflozin or dulaglutide/liraglutide in addition to their insulin regimens.
2. Identify whether the self-titration basal insulin group can achieve goal A1c and fasting blood glucose sooner than the pharmacist-led titration group.
3. Assess readmission rates for patients with diagnosis COPD or HF at Cox Medical Center Branson within 30 days.

## WEDNESDAY, MAY 12, 2021

### Track 3F (3:40 to 5:00)

### Hematology/Oncology

3:40 to 4:00	"Characterization of toxicities of venetoclax in combination with hypomethylating agents in acute myeloid leukemia patients" <b>Amy Lin (PGY2), Nebraska Medicine - Omaha, NE</b>
4:00 to 4:20	"Correlation of Hypocalcemia and Denosumab (Xgeva)" <b>Luke Brinkman (PGY1), Nebraska Medicine - Omaha, NE</b>
4:20 to 4:40	"Evaluation of the Conversion Factor Utilized When Transitioning From Intravenous to Oral Tacrolimus Following Allogeneic Hematopoietic Stem Cell Transplant" <b>Kealy Marth (PGY1), Nebraska Medicine - Omaha, NE</b>
4:40 to 5:00	"Characterizing Infusion Center Ill Visits in Patients with Cancer" <b>Allison Graner (PGY2), Nebraska Medicine - Omaha, NE</b>

#### Program Objectives:

1. To compare the toxicities associated with venetoclax and hypomethylating agents with hypomethylating agents alone in the acute myeloid leukemia population at Nebraska Medicine.
2. Determine the impact of a prescribing alert in the electronic health record on the rates of hypocalcemia in patients receiving denosumab.
3. Determine the optimal IV:PO conversion factor to use in patients post allogeneic hematopoietic stem cell transplant.
4. Identify why patients with cancer are needing additional appointments in hopes to guide further research or implement practice changes that relate to additional medication review or patient education.

### Track 3G (3:40 to 4:40)

### Clinical Services Management

3:40 to 4:00	"The evaluation of pharmacy automated dispensing system stockouts and optimization opportunities" <b>Kate Astrup (PGY1), United Hospital - Saint Paul, MN</b>
4:00 to 4:20	"Defining the Role of a Pharmacist In An Outpatient Oncology Clinic At A Large Community Hospital" <b>Ryan Ragan (PGY2), United Hospital, part of Allina Health - St. Paul, MN</b>
4:20 to 4:40	"Clinical and Financial Impact of Implementation of a Pharmacist Lead System Ambulatory Infusion Coordinator" <b>Laura McKeown (PGY2), CHI Health - Omaha, NE</b>

#### Program Objectives:

1. Evaluate and optimize current automated dispensing system stockout processes to reduce the quantity of stockouts and promote efficient use of pharmacy technician/intern time.
2. Report results of a nationwide survey to identify essential functions of a clinical pharmacist in an outpatient oncology infusion clinic at a 350-bed community hospital.
3. Discuss financial outcomes associated with implementation of a system ambulatory infusion coordinator.

## THURSDAY, MAY 13, 2021

### Track 4A (12:00 to 1:20)

### Critical Care

12:00 to 12:20	"Hypertonic Saline versus Mixed Salt Solution for the Management of Cerebral Edema" <b>Mackenzie Moritz (PGY1), Research Medical Center - Kansas City, MO</b>
12:20 to 12:40	"Association of Low-Dose Ketamine Use with Emergency Department Throughput in Patients with Abdominal Pain" <b>LeFontae McAtee (PGY1), Research Medical Center - Kansas City, MO</b>
12:40 to 1:00	"Incidence of Diabetes Insipidus after Prolonged Vasopressin Infusion for Septic Shock" <b>Michael Rankin (PGY2), Hennepin County Medical Center - Minneapolis, MN</b>
1:00 to 1:20	"Thirty-Day Post Intervention Outcomes Following Mechanical Thrombectomy with or without Alteplase" <b>Alyssa Pollock (PGY1), CHI Health Immanuel - Omaha, NE</b>

#### Program Objectives:

1. Recall that excess chloride load from intravenous hypertonic fluids may lead to adverse outcomes such as acute kidney injury in neurologically critically ill patients with cerebral edema.
2. To determine if patients who are treated for abdominal pain with low doses of ketamine will have faster disposition time than those who are treated with IV opioids.
3. Describe the incidence of transient diabetes insipidus post vasopressin infusion in the medical intensive care population.
4. Compare outcomes data at CHI Health Immanuel between patients who received mechanical thrombectomy alone versus patients who received both alteplase and mechanical thrombectomy.

### Track 4B (12:00 to 1:20)

### Infectious Disease

12:00 to 12:20	"Antimicrobial-infused bone cement plus intravenous antimicrobials versus intravenous antimicrobials alone: a retrospective comparison of acute kidney injury following total joint arthroplasty" <b>Kirby Knutson (PGY1), Sanford Medical Center Fargo - Fargo, ND</b>
12:20 to 12:40	"Cost Benefit Analysis of Dalbavancin and Vancomycin in the Outpatient Setting for Skin and Soft Tissue Infections" <b>Hannah Hemry (PGY1), UntiyPoint Health - Allen Hospital - Waterloo, IA</b>
12:40 to 1:00	"Assessment of antibiotic choice in patients with community-acquired pneumonia with Pseudomonas aeruginosa risk factors" <b>Jesse Burroughs (PGY1), Cox Medical Center Branson - Branson, MO</b>
1:00 to 1:20	"Rates of Clostridium Difficile Infections After Utilization of Best Practice Advisory" <b>Mattison Davidson (PGY1), Mercy Hospital Joplin - Joplin, MO</b>

#### Program Objectives:

1. Investigate if patients receiving antimicrobial-infused bone cement with intravenous antimicrobials are at higher risk of developing acute kidney injury compared to patients receiving intravenous antimicrobials alone.
2. Discuss the cost benefit analysis of dalbavancin and vancomycin treatment regimens when used for skin and soft tissue infections.
3. Identify patients at risk for Pseudomonas aeruginosa community-acquired pneumonia using the DRIP score.
4. To identify the impact of the implementation of the BPA for C. diff prophylaxis utilization and if it reduced the number of hospital-acquired C. diff infections.

### Track 4C (12:00 to 1:20)

### Internal Medicine

12:00 to 12:20	"Desmopressin versus Dextrose in Water for Therapeutic Re-Lowering of Sodium" <b>Caiflin Labay (PGY1), Houston Methodist Hospital - Houston, TX</b>
12:20 to 12:40	"Evaluation of Outcomes with Apixaban use for Venous Thromboembolism in Hospitalized Patients with End-stage Renal Disease Receiving Renal Replacement Therapy" <b>Jingshi Chen (PGY1), Houston Methodist Hospital - Houston, TX</b>
12:40 to 1:00	"Comparison of Baseline Characteristics and Risk Factors for Patients Readmitted within 30 Days of Hospital Discharge with Venous Thromboembolism Events Versus Those Without Venous Thromboembolism" <b>Abdullah Alshehry (PGY1), Houston Methodist Hospital - Houston, TX</b>
1:00 to 1:20	"Incidence of new symptomatic venous thromboembolism in COVID-19 positive patients" <b>McKenzie Magee (PGY1), MercyOne Des Moines Medical Center - Des Moines, IA</b>

#### Program Objectives:

1. Describe the efficacy and safety of three strategies for treatment of overcorrection of hyponatremia.
2. Evaluate potential contributing factors associated with major bleeding in patients with ESRD receiving RRT and with a VTE diagnosis receiving apixaban.
3. Identify hospitalized patients with high risk of readmission with venous thromboembolism.
4. Describe the incidence of VTE in patients with COVID-19 and any risk factors that may increase the risk for VTE.

**Track 4D (12:00 to 1:20)**

**Pharmacy Practice**

<b>12:00 to 12:20</b>	"Impact on Readmission Rates when Pharmacists Review Discharge Medication Reconciliations" <b>Sarah Stone (PGY1), CoxHealth - Springfield, MO</b>
<b>12:20 to 12:40</b>	"Patient Factors Associated with Emergency Department Visit for an Opioid Induced Respiratory Depression Event and Qualification for Naloxone" <b>Kristen Butler (PGY1), MercyOne Des Moines Medical Center - Des Moines, IA</b>
<b>12:40 to 1:00</b>	"The Impact of COVID-19 on Pharmacy Residency Training: A Course Altering Change?" <b>Katherine Winter (PGY1), Nebraska Medicine - Omaha, NE</b>
<b>1:00 to 1:20</b>	"Impact of over-resuscitation in septic patients presenting to the emergency department in an academic medical center" <b>Adam Bassing (PGY1), Creighton University Medical Center - Bergan Mercy - Omaha, NE</b>

**Program Objectives:**

1. Describe a method for assessing pharmacist impact on measurable patient outcomes.
2. Identify patient criteria which may indicate a patient's need for naloxone prior to ED discharge.
3. Establish and characterize a collective snapshot of the impact the COVID-19 pandemic has had on residency training, and identify innovative measures adopted by residency programs to maintain a quality learning and training environment for pharmacy residents.
4. Discuss the potential impact of over-resuscitating septic patients on initial presentation.

**Track 4E (12:00 to 1:20)**

**Primary/Ambulatory Care**

<b>12:00 to 12:20</b>	"Pharmacist Impact on Evidence-based Prescribing of Diabetes Medications in Patients with Clinical Atherosclerotic Cardiovascular Disease(ASCVD)" <b>Caressa Trueman (PGY2), Nebraska Medicine - Omaha, NE</b>
<b>12:20 to 12:40</b>	"Extension of VIONE, a medication deprescribing approach, in a rural Veterans Affairs Health Care System" <b>Rachel Mitchell (PGY1), VA Black Hills Health Care System - Fort Meade, SD</b>
<b>12:40 to 1:00</b>	"Examining outcomes of a pharmacist-managed diabetes program" <b>Nicholas Meyer (PGY1), Sanford Medical Center Fargo - Fargo, ND</b>
<b>1:00 to 1:20</b>	"Use of Electronic Medical Record (EMR) Prescription Transmission Functionality to Decrease Provider Represcribing Burden at Ambulatory Specialty Clinics: A Retrospective Cohort Study" <b>Sammie Nguyen (PGY1), Sanford Medical Center Fargo - Fargo, ND</b>

**Program Objectives:**

1. Describe the extent to which patients with diabetes and clinical ASCVD, who are managed by a PCMH primary care provider, with or without pharmacist diabetes medication management, have medication lists that are consistent with the American Diabetes Association's glucose-lowering treatment guidelines related to the use of GLP-1 agonist and SGLT-2 inhibitor medications.
2. Determine the impact of VIONE implementation into multiple patient-aligned care teams.
3. Discuss the results of a retrospective matched cohort study comparing outcomes in patients referred to a pharmacist-managed diabetes program compared to those undergoing usual care.
4. Describe the impact of implementing an EMR prescription transmission functionality on decreasing provider represcribing burden at ambulatory specialty clinics.

**Track 4F (12:00 to 1:00)**

**Hematology/Oncology**

<b>12:00 to 12:20</b>	"Hyperpigmentation with Capecitabine" <b>Krystal Heinen (PGY1), Hennepin Healthcare - Minneapolis, MN</b>
<b>12:20 to 12:40</b>	"Retrospective Analysis of Trabectedin for Soft Tissue Sarcoma and the Occurrence of Adverse Events" <b>Michelle Sproat (PGY2), Barnes Jewish Hospital - St. Louis, MO</b>
<b>12:40 to 1:00</b>	"Impact of Dosing Weight on Busulfan Pharmacokinetics in Myeloablative Allogeneic Stem Cell Transplant Recipients" <b>Adam Robinson (PGY2), Barnes-Jewish Hospital - Saint Louis, MO</b>

**Program Objectives:**

1. Identify incidence of hyperpigmentation in capecitabine treatment and potential risk factors for hyperpigmentation, as well as if race and/or ethnicity affects the rate of hyperpigmentation.
2. Understand the role and identify the frequency of adverse events from trabectedin in soft tissue sarcoma.
3. Evaluate the busulfan dose adjustments required in order to attain a target busulfan AUC in patients whose weight is greater than or equal to 120% of their IBW and were dosed using IBW compared to CBW20.

**Track 4G (12:00 to 1:20)**

**Community Practice**

<b>12:00 to 12:20</b>	"Implementation of a Self-Measured Blood Pressure Program at a Rural, Independent, Community Pharmacy: A Pilot Study" <b>Heather Jarvis (PGY1), L&amp;S Pharmacy - Charleston, MO</b>
<b>12:20 to 12:40</b>	"The Role of Social Determinants of Health in Adherence of HMG-CoA Reductase Inhibitors in the Community Pharmacy Setting" <b>Dominique Devereux (PGY1), Balls Foods - Price Chopper Pharmacy/UMKC - Raymore, MO</b>
<b>12:40 to 1:00</b>	"Vaccination Approval Literacy and Its Effects on Intention to Receive Future COVID-19 Immunization" <b>Elizabeth Carmosino (PGY1), Balls Foods Stores and The University of Kansas School of Pharmacy - Olathe, KS</b>
<b>1:00 to 1:20</b>	"Evaluating Influenza Vaccine Hesitancy in a COVID-19 Environment" <b>Molly Kabella (PGY1), University of Kansas School of Pharmacy - Lawrence, KS</b>

**Program Objectives:**

1. Describe the implementation of a self-measured blood pressure program within community pharmacy practice.
2. Describe the process to identify a targeted group of patients and administer a social determinant of health screening in a community pharmacy.
3. Relate how knowledge of vaccination approval processes impacts interest in receiving a COVID-19 vaccine.
4. Summarize the hesitations for COVID-19 vaccinations and how the COVID-19 pandemic has altered influenza vaccine hesitations.

**Track 5A (1:30 to 3:10)**

**Critical Care**

<b>1:30 to 1:50</b>	"Evaluating the Tapering of Midodrine in Patients with Refractory Hypotension in an Academic Medical Center" <b>Aaron Lawson (PGY1), Truman Medical Center - Kansas City, MO</b>
<b>1:50 to 2:10</b>	"Safety Comparison of Heparin and Enoxaparin for Venous Thrombosis Prophylaxis in Traumatic Brain Injury" <b>Sara Lauterwasser (PGY2), Truman Medical Center - Kansas City, MO</b>
<b>2:10 to 2:30</b>	"Retrospective Analysis of Patient Outcomes with Angiotensin II (GIAPREZA) use at a Level 1 Trauma Center" <b>Brittney Saunders (PGY1), Regions Hospital - Saint Paul, MN</b>
<b>2:30 to 2:50</b>	"Impact of Multidisciplinary Huddles on time to Antibiotic Administration in Sepsis" <b>Kathryn Sandgren (PGY2), Regions Hospital - Saint Paul, MN</b>
<b>2:50 to 3:10</b>	"Implementation of a Phenobarbital Protocol for Alcohol Withdrawal in the ICU" <b>Lucas Beckman (PGY1), Decatur Memorial Hospital - Decatur, IL</b>

**Program Objectives:**

1. Determine the appropriateness of tapering midodrine when used to treat patients with refractory hypotension.
2. Describe the differences in safety and efficacy when comparing enoxaparin and heparin for the use of venous thrombosis prophylaxis in patients who have experienced a traumatic brain injury.
3. Evaluate the efficacy and clinical benefit in patient outcomes with the addition of ATII to a background vasopressor regimen in fluid-resuscitated vasodilatory shock.
4. Describe the impact of multidisciplinary huddles on time to antibiotic administration for septic patients in an emergency department setting.
5. Clinicians attending this presentation should be able to define the prevalence of delirium tremens, intubations, seizures, and mortality in alcohol withdrawal patients treated with either benzodiazepines or phenobarbital.

**Track 5B (1:30 to 3:10)**

**Infectious Disease**

<b>1:30 to 1:50</b>	"Optimizing vancomycin dosing with area under the curve kinetics in patients with severe methicillin-resistant Staphylococcus aureus infections" <b>Anna Timmerberg (PGY1), North Kansas City Hospital - North Kansas City, MO</b>
<b>1:50 to 2:10</b>	"Ceftaroline vs. Vancomycin With Piperacillin/tazobactam or Cefepime or Ceftazidime and Effect on Length of Stay" <b>Alexis Kokett (PGY1), Fargo VA Health Care System - Fargo, ND</b>
<b>2:10 to 2:30</b>	"Impact of Iron Supplementation on Hospital Length of Stay for Pneumonia or Skin and Skin Structure Infection" <b>Isaac Nies (PGY1), Fargo VA Health Care System - Fargo, ND</b>
<b>2:30 to 2:50</b>	"Clostridioides difficile Treatment Outcomes Post-Implementation of 2018 Guidelines at a Community Hospital" <b>Heejung Woo (PGY1), Southeast Hospital - Cape Girardeau, MO</b>
<b>2:50 to 3:10</b>	"Evaluation of Vancomycin use in Hospitalized Patients with Febrile Neutropenia Receiving Cancer Treatment" <b>Ryan Wooldridge (PGY1), The University of Kansas Health System St. Francis Campus - Topeka, KS</b>

**Program Objectives:**

1. Evaluate target attainment at steady state following the conversion to AUC monitoring from trough monitoring of vancomycin.
2. Identify whether there is a difference in length of stay following use of ceftaroline compared to vancomycin plus piperacillin/tazobactam or cefepime or ceftazidime for treatment of infections requiring hospitalization.
3. Describe the impact of iron supplementation on hospital length of stay for pneumonia or skin and skin structure infection.
4. Review the recurrence rates of CDI treatments before and after 2018 IDSA/SHEA guidelines implementation in a community hospital setting.
5. The purpose of this study is to evaluate vancomycin use in patients meeting febrile neutropenia guideline recommendations at The University of Kansas Health System St. Francis Campus.

**Track 5C (1:30 to 2:30)**

**Internal Medicine**

<b>1:30 to 1:50</b>	"Evaluation of Inpatient Antipsychotic Utilization in Older Adult Patients with Delirium" <b>Kelcy Sorensen (PGY1), Avera McKennan Hospital &amp; University Health Center - Sioux Falls, SD</b>
<b>1:50 to 2:10</b>	"Enoxaparin Anti-Xa Monitoring for Venous Thromboembolism Prophylaxis in Trauma Patients at an Academic Medical Center" <b>Zachary Muller (PGY1), Avera McKennan Hospital &amp; University Health Center - Sioux Falls, SD</b>
<b>2:10 to 2:30</b>	"Evaluating the safety of dexmedetomidine on non-ICU units for alcohol withdrawal and delirium" <b>Taylor Rothenberger (PGY1), Avera McKennan Hospital &amp; University Health Center - Sioux Falls, SD</b>

**Program Objectives:**

1. Evaluate utilization of haloperidol in older adult patients 65 years of age & older with delirium before & after implementation of Nursing Delirium Screening Scale (NuDESC) assessments with inpatient haloperidol orders.
2. Discuss the incidence of sub-prophylactic enoxaparin trough levels in trauma patients and the potential impact of these levels on patient outcomes.
3. Evaluate the safety of dexmedetomidine use on non-ICU floors at a lower maximum rate of 0.7 mcg/kg/hour, compared to the ICU maximum rate of 1.5 mcg/kg/hour, for alcohol withdrawal and delirium.

**Track 5D (1:30 to 3:10)**

**Pharmacy Practice**

<b>1:30 to 1:50</b>	"Formulary Management in Missouri and Kansas Rural Healthcare Organizations" <b>Julie Bays (PGY1), University of Missouri-Kansas City - Kansas City, MO</b>
<b>1:50 to 2:10</b>	"Relationship Between COVID-19 Information Sources and Willingness to be Vaccinated Among University Students" <b>Matthew Rugsis (PGY1), University of Missouri-Kansas City Drug Information Center - Kansas City, MO</b>
<b>2:10 to 2:30</b>	"Multisite Assessment of Pharmacy Student Perspectives of the Layered Learning Model in Experiential Education" <b>Tori Rude (PGY1), Lake Region Healthcare - Fergus Falls, MN</b>
<b>2:30 to 2:50</b>	"Impact of pharmacist medication assessment in patients with high fall risk at a community teaching hospital" <b>Victoria Smith (PGY1), UnityPoint Health Des Moines - West Des Moines, IA</b>
<b>2:50 to 3:10</b>	"Pharmacist Impact on Reducing Medication Costs for Patients & Decreasing Medication Waste: Implementation and Expansion of the South Dakota Drug Repository Pilot Program" <b>Amanda Kuhn (PGY2), Avera McKennan Hospital &amp; University Health Center - Sioux Falls, SD</b>

**Program Objectives:**

1. Describe the ways in which rural and/or smaller Midwest hospitals handle the burden of formulary management and identify opportunity to better support these institutions.
2. Identify how healthcare professional and undergraduate students obtain health information and how this and other factors influence health-related decisions.
3. Explain the impact of the layered learning practice model on pharmacy students' perceived ability to participate in core EPAs.
4. Describe the impact of pharmacist medication assessment for admitted patients with high fall risk.
5. Understand the process to operationalize and expand the South Dakota Drug Repository Pilot program, and identify cost and time savings for patients along with potential cost to pharmacies that participate.

**Track 5E (1:30 to 2:50)**

**Primary/Ambulatory Care**

<b>1:30 to 1:50</b>	"Clinical and financial impact of ambulatory care pharmacist-led hypertensive medication management in a family medicine clinic" <b>Ben Modrell (PGY2), CoxHealth - Springfield, MO</b>
<b>1:50 to 2:10</b>	"Effect of medication delivery to bedside on readmission rates" <b>Nicole Diveley (PGY2), CoxHealth - Springfield, MO</b>
<b>2:10 to 2:30</b>	"Reducing readmission rates for chronic obstructive pulmonary disease patients through targeted ambulatory care pharmacist interventions" <b>Sarah Lothspeich (PGY2), CoxHealth - Springfield, MO</b>
<b>2:30 to 2:50</b>	"Prediabetes Management within Veterans Affairs Nebraska-Western Iowa Health Care System (VA NWIHCS)" <b>Quyenn Vu (PGY1), VA Nebraska-Western Iowa Health Care System - Lincoln - Lincoln, NE</b>

**Program Objectives:**

1. Determine impact of pharmacist-led hypertensive medication management on the change in blood pressure from baseline compared to standard care over a one-year period.
2. Identify the effect medication delivery to bedside has on readmission rates for patients discharging from a rehabilitation unit.
3. Describe opportunities for ambulatory care pharmacist interventions to prevent chronic obstructive pulmonary disease (COPD) readmissions.
4. Evaluate current prediabetes management within VA NWIHCS. Discuss different methods of improving management practices for prediabetic patients within VA NWIHCS.

**Track 5F (1:30 to 2:50)**

**Cardiology**

<b>1:30 to 1:50</b>	"Evaluation of Thrombocytopenia in Patients Receiving Percutaneous Mechanical Circulatory Support with an Impella® Device" <b>Erin Houry (PGY1), SSM Health Saint Louis University Hospital - Saint Louis, MO</b>
<b>1:50 to 2:10</b>	"Efficacy and Safety of Pharmacist Led Warfarin Dosing in a Community Hospital Setting" <b>Rouba Abukwaik (PGY1), CHI Health St. Elizabeth - Lincoln, NE</b>
<b>2:10 to 2:30</b>	"Impact of Abnormal Electrolytes on Dofetilide (Tikosyn) Initiation: A Pilot Study" <b>Emily Humphrey (PGY1), Mercy Hospital Springfield - Springfield, MO</b>
<b>2:30 to 2:50</b>	"Effects of body mass index on thrombotic and bleeding outcomes in patients receiving direct oral anticoagulant therapy" <b>Alyssa White (PGY1), North Kansas City Hospital - North Kansas City, MO</b>

**Program Objectives:**

1. Describe the timeline of thrombocytopenia in patients receiving percutaneous mechanical circulatory support with an Impella® device.
2. Identify the strengths of having a pharmacist led warfarin dosing program by comparing the time INR levels are maintained in therapeutic range when pharmacists versus providers dose warfarin.
3. Recognize the impact abnormal electrolytes can have on dofetilide initiation and identify areas for improvement in our current process.
4. Identify if morbid obesity has an effect on thrombotic and bleeding outcomes of patients on direct oral anticoagulant therapy.



**Track 5G (2:30 to 3:10)**

**Clinical Services Management**

<b>2:30 to 2:50</b>	"Assessing the impact of adherence to antipsychotics medications on the rate of rehospitalization in patients with illicit drug use" <b>Paa Kwasi Adjei-frimpong (PGY1), Carefirst BlueCrossBlueShield - Washington, DC</b>
<b>2:50 to 3:10</b>	"Evaluation of an anti-factor Xa unfractionated heparin monitoring and dosing protocol at a regional medical center" <b>Tram Nguyen (PGY1), CHI Health St.Elizabeth - Lincoln , NE</b>

**Program Objectives:**

1. To assess if higher adherence to antipsychotic medications will reduce the hospitalization rate in patients with illicit drug use.
2. Describe the use of an anti-factor Xa for heparin infusion management and monitoring at CHI Health St.Elizabeth.

**Track 5H (1:30 to 2:30)**

**Pediatrics/Neonatology**

<b>1:30 to 1:50</b>	"Impact of Increased Caffeine Dose on Ventilation Days in Preterm Neonates" <b>Taylor Lenz (PGY1), Creighton University Medical Center- Bergan Mercy - Omaha, NE</b>
<b>1:50 to 2:10</b>	"Analysis of the neonatal early-onset sepsis calculator and its impact on antibiotic use at an academic medical center" <b>Emily Oliver (PGY1), CHI Health Creighton University Medical Center - Bergan Mercy - Omaha, NE</b>
<b>2:10 to 2:30</b>	"Evaluation of Initial Vancomycin Dosages and Subsequent Initial Trough Levels Before and After Implementing a Pharmacy to Dose Model" <b>Kelsey Haywood (PGY1), Children's Hospital and Medical Center - Omaha, NE</b>

**Program Objectives:**

1. Identify the optimal dose of caffeine for preterm neonates.
2. Identify the impact implementing the Neonatal Early-Onset Sepsis Calculator made on neonatal antibiotic use at an academic medical center.
3. Examine the effects a pharmacist led vancomycin dosing protocol has on dose optimization and initial trough values through a quality improvement initiative.

**Track 6A (3:20 to 5:00)**

**Critical Care**

<b>3:20 to 3:40</b>	"Predicting Vasopressin Response in Septic Shock" <b>Aileen Scheibner (PGY2), Barnes-Jewish Hospital - St. Louis, MO</b>
<b>3:40 to 4:00</b>	"The Safety and Efficacy of Push Dose Vasopressors in Critically Ill Adults " <b>Sarah Singer (PGY1), Barnes-Jewish Hospital - St. Louis, MO</b>
<b>4:00 to 4:20</b>	"Impact of Emergency Medicine Pharmacists on time to Antibiotic Administration in Patients with Severe Sepsis and Septic Shock in the Emergency Department" <b>Samantha Katzman (PGY2), MercyOne Des Moines Medical Center - Des Moines, IA</b>
<b>4:20 to 4:40</b>	"Retrospective evaluation of phenobarbital compared to standard benzodiazepine therapy for alcohol withdrawal patients in the intensive care unit at an academic medical center" <b>Cassandra Walters (PGY1), CHI Health Creighton University Medical Center-Bergan Mercy - Omaha, NE</b>
<b>4:40 to 5:00</b>	"Evaluation of thromboembolic events and anticoagulant strategies in COVID-19 patients: a retrospective analysis" <b>Jessel Lyn Dela Cruz (PGY1), CHI Health CUMC Bergan Mercy - Omaha, NE</b>

**Program Objectives:**

1. Describe the patient and treatment characteristics that may predict vasopressin response in patients with septic shock.
2. Examine push dose pressor practice patterns in critically ill patients outside of the operating room. Furthermore, we aim to describe overall use, determine efficacy and identify adverse drug events.
3. Evaluate the potential impact of a pharmacist practicing at the bedside on time to antibiotic administration in septic patients.
4. Determine if the use of phenobarbital decreases benzodiazepine requirement in alcohol withdrawal patients requiring ICU care.
5. Identify effective and safe thromboprophylaxis strategies for hospitalized COVID-19 patients.

**Track 6B (3:20 to 5:00)**

**Infectious Disease**

<b>3:20 to 3:40</b>	"Antibiotic course completion and appropriateness in patients who are incarcerated" <b>Shannon Carboni (PGY2), Hennepin Healthcare - Minneapolis, MN</b>
<b>3:40 to 4:00</b>	"Retrospective review of various anticoagulant dosing on preventing thromboembolic events in COVID-19 patients at a community teaching hospital" <b>Diem Huynh (PGY1), Freeman Health System - Joplin, MO</b>
<b>4:00 to 4:20</b>	"Establishing a Pharmacy-led Protocol for Ordering MRSA PCR Nasal Swabs for the De-escalation of Empiric Vancomycin in Pneumonia Patients" <b>Ryan Molander (PGY1), MercyOne Waterloo Medical Center - Waterloo, IA</b>
<b>4:20 to 4:40</b>	"Optimizing Antibiotics in Patients with Leukemia Associated Febrile Neutropenia: Initiation and Discontinuation" <b>Sean Byrne (PGY1), Park Nicollet Methodist Hospital - St. Louis Park, MN</b>
<b>4:40 to 5:00</b>	"Analysis of the utilization and safety of cefprozil plus metronidazole in patients with acute uncomplicated diverticulitis. " <b>Christine Behrendt (PGY1), Park Nicollet Methodist Hospital - St. Louis Park, MN</b>

**Program Objectives:**

1. Describe number of prescribed antibiotic courses that are completed at the Hennepin County Adult Detention Center and the number of infection-related healthcare contacts (ED, EMS, urgent care, hospital, and pharmacy visits) within 30 days of jail discharge. Discuss the patient characteristics associated with course completion.
2. To evaluate the impact of varying doses of unfractionated heparin and low molecular weight heparin on preventing thromboembolic events.
3. Recognize the value of MRSA PCR nasal swabs in pneumonia patients receiving vancomycin therapy and describe how implementing pharmacist-led protocols can improve patient care .
4. Analyze antibiotic initiation in acute leukemia patients with febrile neutropenia to assess if antibiotics are being started within 30 minutes from fever onset. Establish antibiotic discontinuation criteria in febrile neutropenic patients to optimize antibiotic use at initiation and discontinuation
5. Describe the trends in infection resolution, treatment failure, and reinfection rates as well as adverse events associated with antimicrobial therapy prescribed for acute uncomplicated diverticulitis at Park Nicollet Methodist Hospital. Understand how to apply this information and antimicrobial stewardship principles to appropriately treat this patient population.

**Track 6C (3:20 to 4:00)**

**Internal Medicine**

<b>3:20 to 3:40</b>	"Steroid Overlap Therapy in COPD Exacerbations" <b>Aaron Hunsaker (PGY1), Nebraska Medicine - Omaha, NE</b>
<b>3:40 to 4:00</b>	"Impact of Hospital Administration of Intramuscular Naltrexone in Patients with Alcohol Use Disorder" <b>Jeremy Tigh (PGY1), Nebraska Medicine - Omaha, NE</b>

**Program Objectives:**

1. Discuss the impact that steroid overlap therapy has on length of stay in patients with a diagnosis of COPD exacerbations.
2. Discuss whether inpatient administration of long-acting intramuscular naltrexone decreases hospital readmission rates and harm in patients with alcohol use disorder.

**Track 6D (4:20 to 5:00)**

**Hematology/Oncology**

<b>4:20 to 4:40</b>	"Prevention of venous thromboembolism in the ambulatory care oncology patient" <b>Karli Welter (PGY1), UnityPoint Health Allen Hospital - Waterloo, IA</b>
<b>4:40 to 5:00</b>	"Development of a Biosimilar Adoption Program for Rituximab Biosimilar in a Community Hospital" <b>Nhi Bui (PGY1), CoxHealth Medical Center - Springfield, MO</b>

**Program Objectives:**

1. Identify oncology patients at high risk of venous thromboembolism.
2. Describe the biosimilar adoption process. Identify unknown barriers throughout the biosimilar adoption process. Review the adoption rate of rituximab biosimilar. Report the budget impact for the health system.

**Track 6E (4:00 to 5:00)**

**Cardiology**

<b>4:00 to 4:20</b>	"No Need to Bleed: Enoxaparin Bridging in LVADs" <b>Nathan Jones (PGY1), Houston Methodist Hospital - Houston, TX</b>
<b>4:20 to 4:40</b>	"Apixaban and Rivaroxaban Monitoring in Acute Kidney Injury" <b>William Towers (PGY2), Houston Methodist Hospital - Houston, TX</b>
<b>4:40 to 5:00</b>	"Incidence of Gastrointestinal Bleeding Events in Patients with Left-ventricular Assist Device (LVAD) on Statin Versus Patients with LVAD not on Statin Therapy" <b>Hala Halawi (PGY1), Houston Methodist Hospital - Houston, TX</b>

**Program Objectives:**

1. Identify the associated safety of Anti-Xa guided enoxaparin dosing for warfarin bridging in patients with Left Ventricular Assist Device.
2. Describe potential factors associated with major bleeding in hospitalized patients who experience acute kidney injury while receiving apixaban or rivaroxaban.
3. Describe the impact of statin therapy on the incidence of GIB events in patients with left-ventricular assist devices within one year of device implantation.

**Track 6F (4:00 to 5:00)**

**Community Practice**

<b>4:00 to 4:20</b>	"A Pharmacist-led Educational Intervention to Increase Medication Adherence Among Cholesterol, Blood Pressure, and Diabetes Medications Fixing the MisDIRecting Issues and Leading to a UniDIRrectional Solution" <b>Armen Topouzian (PGY1), HomeTown Pharmacy - Newaygo, MI</b>
<b>4:20 to 4:40</b>	"The COVID-19 Vaccine Conundrum - An Assessment of Vaccine Hesitancy Amongst Patients at a Federally Qualified Health Center " <b>Letoia Clark (PGY1), KC CARE Health Center - Kansas City, MO</b>
<b>4:40 to 5:00</b>	"Impact of a pharmacist-led preventative screening intervention during comprehensive medication reviews" <b>Jordan Frangello (PGY1), Walgreens Community-Based Specialty - Kansas City, MO</b>

**Program Objectives:**

1. Identify benefits of medication adherence, including those related to health and financial considerations, determine the impact of DIR fees on the participants pharmacy and how to mitigate DIR fees to the extent possible, and recognize barriers to medication adherence among different populations .
2. Identify perceived patient-reported barriers associated with receiving a COVID-19 vaccine.
3. To evaluate the impact of a pharmacist-led preventative screening intervention during a comprehensive medication review (CMR) at a specialty community pharmacy in the Kansas City Urban Core.

**Track 6G (4:20 to 5:00)**

**Transplant**

<b>4:20 to 4:40</b>	"Immediate Versus Delayed Cytomegalovirus Prophylaxis in Kidney Transplant Recipients" <b>Aaron Hutchins (PGY2), Nebraska Medicine - Omaha, NE</b>
<b>4:40 to 5:00</b>	"Evaluation of Expansion of Pharmacy Services for Kidney Transplant Recipients" <b>Melissa Borsh (PGY1), Nebraska Medicine - Omaha, NE</b>

**Program Objectives:**

1. Discuss whether delaying the initiation of CMV antiviral prophylaxis to POD7 or day of discharge affects the incidence of CMV infection or CMV disease after kidney transplantation.
2. Discuss whether the change of pharmacy services at Nebraska Medicine has contributed to a decreased hospital stay and improved outcomes for kidney transplant recipients.

**Track 6H (3:20 to 4:00)**

**Clinical Services Management**

<b>3:20 to 3:40</b>	"Patient Safety and Financial Outcomes of Smart Pump - Electronic Health Record Interoperability" <b>Wenfei Wei (PGY1), Houston Methodist Hospital - Houston, TX</b>
<b>3:40 to 4:00</b>	"Retrospective Analysis of Pharmacy-Led Medication Reconciliations at Transitions of Care and Its Impact on Clinical Outcomes" <b>Natalie Tiefenthaler (PGY1), CUMC-Bergan Mercy - Omaha, NE</b>

**Program Objectives:**

1. Discuss potential clinical and financial outcomes of implementing smart pump - EHR interoperability at the learner's institution.
2. Identify the most clinically relevant time to conduct a pharmacist-led medication reconciliation.

**Track 6I (4:00 to 5:00)**

**Psychology**

<b>4:00 to 4:20</b>	"Clinical Impact of Pharmacogenomic Testing in Patients with Treatment-resistant Depression" <b>Kaitlyn Riggs (PGY1), SSM Health DePaul Hospital - St. Louis, MO</b>
<b>4:20 to 4:40</b>	"Metformin for the Prevention of Antipsychotic-Induced Weight Gain and Metabolic Abnormalities in a Veteran Population" <b>Courtney Younge (PGY1), Sioux Falls VA Health Care System - Sioux Falls , SD</b>
<b>4:40 to 5:00</b>	"Metabolic Monitoring of Second Generation Antipsychotics" <b>Ashton Forst (PGY1), Hennepin Healthcare - Minneapolis, MN</b>

**Program Objectives:**

1. Identify the impact of variable CYP450 metabolism and its ability to predict medication response in patients with treatment-resistant depression.
2. To identify whether or not metformin, started at any time in the patient's clinical course of treatment, can prevent antipsychotic-induced weight gain and metabolic abnormalities.
3. The learning objective of this research project was to assess metabolic monitoring of second generation antipsychotics at an Adult Outpatient Psychiatry Clinic. Additionally, to assess how education that is developed and implemented based on the findings impacts metabolic monitoring in the future.

**Track 7A (12:00 to 1:40)**

**Critical Care**

<b>12:00 to 12:20</b>	"Effect of norepinephrine versus vasopressin on pulmonary artery pressure" <b>Grace Korkames (PGY2), Nebraska Medicine - Omaha, NE</b>
<b>12:20 to 12:40</b>	"Hemodynamic and ECMO flow response to albumin versus crystalloid therapy" <b>Jessica Prucha (PGY2), Nebraska Medicine - Omaha, NE</b>
<b>12:40 to 1:00</b>	"Evaluation of a Multidisciplinary Electronic Discharge Medication Prescribing Process in an Academic Center's Emergency Department" <b>Brett Young (PGY2), Nebraska Medicine - Omaha, NE</b>
<b>1:00 to 1:20</b>	"Evaluation of Liposomal Bupivacaine for Post-Operative Pain Management in Cardiothoracic Surgery Patients" <b>Bailey Buenger (PGY1), Nebraska Medicine - Omaha, NE</b>
<b>1:20 to 1:40</b>	"Evaluation of Intravenous Ketorolac in Cardiothoracic Surgery Patients" <b>Amanda Vanderwerf (PGY1), Nebraska Medicine - Omaha, NE</b>

**Program Objectives:**

1. Describe the effect norepinephrine and vasopressin on pulmonary and systemic hemodynamic parameters.
2. Discuss the impact of albumin versus crystalloid fluid resuscitation strategies on fluid status and hemodynamic response in patients on extracorporeal membrane oxygenation therapy.
3. Evaluate the success of the novel multidisciplinary electronic discharge prescription process on length of stay in an Academic Center's emergency department.
4. Describe the impact of liposomal bupivacaine on the amount of opioids used post-operatively in cardiothoracic surgery patients.
5. Evaluate the impact of intravenous ketorolac on post-operative opioid use in cardiothoracic surgery patients undergoing coronary artery bypass grafting (CABG).

**Track 7B (12:00 to 1:40)**

**Infectious Disease**

<b>12:00 to 12:20</b>	"Comparison of Driveline Debridement Plus Antimicrobials Versus Antimicrobials Alone For Treatment of Driveline Infections." <b>Julie Hubbard (PGY1), Barnes Jewish Hospital - St. Louis, MO</b>
<b>12:20 to 12:40</b>	"Assessment of Spectrum Score-based Antibiotic De-escalation in Patients with Nosocomial Pneumonia" <b>Daniel Ilges (PGY2), Barnes-Jewish Hospital - Saint Louis, MO</b>
<b>12:40 to 1:00</b>	"The Reliability of Blood Culture Identification by Rapid PCR Compared to Cultured Organism" <b>Kyle Gibbons (PGY2), Avera McKennan Hospital &amp; University Health Center - Sioux Falls, SD</b>
<b>1:00 to 1:40</b>	"Process of implementing vancomycin area under the concentration-time curve monitoring program in a Veterans Affairs Health Care System" <b>Rebecca Hassing (PGY1) and Kateri Petto (PGY1), VA Nebraska-Western Iowa Health Care System - Omaha - Omaha, NE</b>

**Program Objectives:**

1. This study will focus on management of driveline infections, determining whether driveline debridement with antibiotics vs antibiotic administration alone will lead to greater long-term survival, free of worsening infection.
2. Explain how spectrum scores can be used to assess antibiotic de-escalation.
3. Discuss the reliability of the BioFire® BCID compared to cultured organism at a 300-bed teaching hospital.
4. List components of our transition to AUC design and monitoring of vancomycin using the Bayesian software program PrecisePK. Discuss the accuracy of AUC estimations provided by PrecisePK within the veteran population.

**Track 7C (12:00 to 1:20)**

**Internal Medicine**

<b>12:00 to 12:20</b>	"Evaluation of Treatment-Dose Enoxaparin in Morbidly Obese Patients at an Academic Health Center" <b>Carly Guay (PGY2), University of Missouri Health Care - Columbia, MO</b>
<b>12:20 to 12:40</b>	"Venous Thromboembolism Prophylaxis Post Total Knee Arthroplasty or Total Hip Arthroplasty: A Retrospective Analysis" <b>Amanda Dickinson (PGY1), Monument Health Rapid City Hospital - Rapid City, SD</b>
<b>12:40 to 1:00</b>	"Evaluation of Ivermectin as a Treatment for COVID-19: A Retrospective Cohort Study" <b>Joseph Mauer (PGY1), Trinity Health - Minot, ND</b>
<b>1:00 to 1:20</b>	"The Impact of Time to Intravenous Calcium Administration in Hyperkalemia on Patient Mortality" <b>Elizabeth Sundberg (PGY2), Barnes-Jewish Hospital - St. Louis, MO</b>

**Program Objectives:**

1. Describe current dosing and monitoring trends for treatment-dose enoxaparin in morbidly obese patients at University of Missouri Health Care, and identify areas for improvement related to the use of treatment-dose enoxaparin in this population.
2. Identify the VTE prophylaxis agent associated with the most readmissions for VTE or clinically significant bleeding in patients who underwent TKA or THA at Monument Health Rapid City Hospital and the Monument Health Orthopedic & Specialty Hospital.
3. Define the role of ivermectin in the treatment of hospitalized COVID-19 patients.
4. Evaluate the effect of time to IV calcium administration on inpatient mortality in hyperkalemia.

**Track 7D (12:00 to 1:00)**

**Pharmacy Practice**

<b>12:00 to 12:20</b>	"Evaluation of inpatient promethazine utilization and implementation of ISMP best practice" <b>Jaimyn Prost (PGY1), North Kansas City Hospital - North Kansas City, MO</b>
<b>12:20 to 12:40</b>	"Understanding Clinical Characteristics in Patients Taking Aspirin 325mg that Impacts Discontinuation, Dose Reduction, or Continuation of Therapy" <b>Ashleigh Wallace-Lacey (PGY2), Veterans Affairs Heartland Network West - Kansas City, MO</b>
<b>12:40 to 1:00</b>	"Evaluation of Healthcare Professionals' Perspectives on Medical Cannabis in Iowa" <b>Sarah Kadura (PGY1), Northeast Iowa Family Practice Center - Waterloo, IA</b>

**Program Objectives:**

1. To evaluate promethazine utilization, safety, and efficacy in inpatients at North Kansas City Hospital.
2. Identify patient clinical characteristics associated with discontinuation, dose reduction, or continuation of aspirin 325mg therapy. Identify VA providers' clinical reasoning associated with discontinuation, dose reduction, or continuation of aspirin 325mg therapy.
3. Identify Iowa healthcare professionals' opinions regarding medical cannabis and how it is provided in Iowa.

**Track 7E (12:00 to 1:00)**

**Primary/Ambulatory Care**

<b>12:00 to 12:20</b>	"Talking with Pharmacists can Improve Health Outcomes, So Call Me, Maybe?" <b>Kristin Orpin (PGY1), Tria Health - Overland Park, KS</b>
<b>12:20 to 1:00</b>	"Evaluation of the Management of Testosterone Replacement Therapy in a Veterans Affairs Health Care System" <b>Rebecca Metcalf (PGY1) and Alec Gates (PGY1), VA Nebraska-Western Iowa Health Care System - Omaha - Omaha, NE</b>

**Program Objectives:**

1. Identify the impact of clinical pharmacist-led telephonic consults in improving patient care by closing clinical care gaps.
2. Identify areas for improvement in TRT management at our institution to increase adherence to guideline directed therapy.

**Track 7F (12:00 to 12:40)**

**Hematology/Oncology**

<b>12:00 to 12:20</b>	"Assessment and implementation of a tool to monitor patient adherence to oral chemotherapy" <b>Marianne Carter (PGY1), LMH Health - Lawrence, KS</b>
<b>12:20 to 12:40</b>	"Efficacy of Direct Oral Anticoagulants in the Prevention of Recurrent Deep Vein Thrombosis in Obese Veterans versus Veterans of Normal Weight" <b>Hannah Twenhafel (PGY1), VA Eastern Kansas Health Care System - Topeka, KS</b>

**Program Objectives:**

1. Review the importance of oral chemotherapy adherence and describe a tool to monitor patient adherence.
2. To determine whether Direct Oral Anticoagulants (DOACs) are as effective at preventing a recurrent deep vein thrombosis (DVT) in obese Veterans as they are in Veterans of normal weight. Additionally, to determine the rate of major bleeding events in obese Veterans taking a DOAC.

**Track 7G (12:00 to 1:00)**

**Cardiology**

<b>12:00 to 12:20</b>	"Evaluation of Bleeding Events Related to Unnecessary Aspirin Use in a Non-profit, Community-based Hospital" <b>Paul Scholbrock (PGY1), Mercy Medical Center - Cedar Rapids - Cedar Rapids, IA</b>
<b>12:20 to 12:40</b>	"Implementation of a venous thromboembolism prophylaxis protocol for traumatic brain injury patients" <b>Nikki Owen (PGY1), Bryan Medical Center - Lincoln, NE</b>
<b>12:40 to 1:00</b>	"Cardiac monitoring of QTc prolonging agents in hospitalization" <b>Cole Borchardt (PGY1), MercyOne North Iowa Medical Center - Mason City, IA</b>

**Program Objectives:**

1. Be able to determine when aspirin for primary prevention would be appropriate based upon new guideline recommendations.
2. Assess the incidence of venous thromboembolism and intracranial hemorrhage compared to timing of venous thromboembolism pharmacologic prophylaxis initiation in patients at Bryan Medical Center - West Campus.
3. Identify appropriate follow-up EKG monitoring post initiation of QTc prolonging agent(s).

**Track 7H (12:00 to 1:40)**

**Critical Care**

<b>12:00 to 12:20</b>	"Levodocarnitine Supplementation in Patients with Hepatic Dysfunction and Hyperammonemia" <b>Matthew Winters (PGY2), Hennepin Healthcare - Minneapolis, MN</b>
<b>12:20 to 12:40</b>	"Impact of a Pharmacist-Led Urine Culture Review Protocol in a Large, Urban Emergency Department and Urgent Care" <b>Maggie Sundstrom (PGY2), Hennepin Healthcare - Minneapolis, MN</b>
<b>12:40 to 1:00</b>	"Defining Bleeding Characteristics in Frostbite Patients Managed with tPA" <b>Jenna Murphy (PGY1), Hennepin Healthcare - Minneapolis, MN</b>
<b>1:00 to 1:20</b>	"Emergency Medicine Pharmacist Impact on Time-Sensitive Medications" <b>Jenna Lund (PGY2), Monument Health Rapid City Hospital - Rapid City, SD</b>
<b>1:20 to 1:40</b>	"Utilization of Midodrine as an Adjunct to Intravenous (IV) Vasopressors to Reduce Vasopressor Dose and Duration" <b>Muhammed Ceesay (PGY1), Avera McKennan Hospital &amp; University Health Center - Sioux Falls, SD</b>

**Program Objectives:**

1. Describe the institutional use of levocarnitine supplementation in patients with hepatic dysfunction and hyperammonemia.
2. Describe the impact of a pharmacist-led urine culture review program at a large, urban emergency department and urgent care.
3. Describe the relationship between tPA use and clinically relevant bleeding in patients with frostbite.
4. Describe the impact of pharmacist presence on administration of time-sensitive medications in sepsis, shock, febrile neutropenia and stroke in the emergency department.
5. Discuss the efficacy of midodrine as an adjunct to intravenous vasopressors to reduce vasopressor dose and duration.

**Track 7I (12:00 to 1:20)**

**Infectious Disease**

<b>12:00 to 12:20</b>	"Multicenter evaluation of superinfection occurrence and impact on clinical outcomes in patients with COVID-19" <b>Taryn Eubank (PGY2), Houston Methodist Hospital - Houston, TX</b>
<b>12:20 to 12:40</b>	"Characterization of carbapenem-resistant Enterobacterales at a large urban health system" <b>Melissa ONeal (PGY1), Houston Methodist Hospital - Houston, TX</b>
<b>12:40 to 1:00</b>	"Clinical Cure Associated With Nafcillin Compared to Cefazolin Use for Methicillin-Susceptible Staphylococcus Aureus (MSSA) Endocarditis at an Academic Medical Center" <b>Hannah Michael (PGY1), University of Missouri Health Care - Columbia, MO</b>
<b>1:00 to 1:20</b>	"Aminoglycoside and vancomycin dosing in pregnant patients" <b>Jamie Prashek (PGY1), University of Missouri Health Care-University Hospital - Columbia, MO</b>

**Program Objectives:**

1. Identify the occurrence of superinfections in patients with COVID-19. Describe the risk factors of superinfection occurrence for patients with COVID-19.
2. Describe the in vitro susceptibility of carbapenem-resistant E. coli and K. pneumoniae isolates across a large hospital system and report clinical outcomes of the infections caused by these bacteria.
3. Describe the comparative effectiveness of cefazolin to nafcillin for MSSA infective endocarditis at University of Missouri Health Care and implications in clinical practice.
4. Be able to recognize aminoglycoside agent(s) to use, as well as discuss safe and efficacious doses of aminoglycosides and vancomycin in females during pregnancy.

**Track 7J (12:00 to 12:40)**

**Psychology**

<b>12:00 to 12:20</b>	"Implementation of a Medication-assisted Treatment (MAT) Program within an Inpatient Psychiatric Hospital" <b>Brooke Bernu (PGY2), Avera Behavioral Health Hospital - Sioux Falls, SD</b>
<b>12:20 to 12:40</b>	"Evaluation of Pharmacist-led Medication Group on Medication Adherence in Psychiatric Inpatients" <b>Jennifer Tran (PGY1), Mercy Hospital Springfield - Springfield, MO</b>

**Program Objectives:**

1. Identify benefits of implementing a medication-assisted treatment (MAT) program within an inpatient psychiatric hospital.
2. Discuss the effects of pharmacist-led medication group on 90-day medication adherence post discharge.